CTS Corporation (CTS) Q1 2026 earnings review
Diversification Strategy Delivers Growth and Expanding Margins
CTS Corporation delivered a strong first quarter, accelerating revenue growth to 11% YoY and expanding margins significantly. The results powerfully validate management's multi-year strategy to pivot away from legacy transportation markets toward higher-margin diversified end markets (Medical, Industrial, Aerospace & Defense). Diversified sales surged 18% YoY, driving Adjusted Gross Margin up 250 basis points to 39.5%. Even the lagging Transportation segment stabilized, reversing from previous declines to post 3% growth. Fueled by this momentum, management narrowed and raised the lower end of its full-year 2026 guidance.
🐂 Bull Case
The mix shift toward Diversified End Markets (now 57% of total sales) is fundamentally improving profitability. Adjusted EBITDA margin expanded to 23.0%, proving the company can achieve higher steady-state margins as it reduces reliance on the automotive cycle.
Medical sales rocketed 28% YoY while Industrial climbed 14%. Healthy book-to-bill ratios in these segments (1.20 and 1.29 respectively) signal that end-market demand is durable and provides high visibility for the rest of the year.
🐻 Bear Case
Despite the overall strong bookings picture, Aerospace & Defense suffered a weak 0.75 book-to-bill ratio. Management acknowledged program funding delays, introducing uncertainty and reliance on government budget cycles.
The company is actively fighting Section 232 tariffs on steel and aluminum, alongside inflation in precious metals and petroleum-based products. If pricing power wanes, these input costs could quickly compress the newly expanded margins.
⚖️ Verdict: 🟢
Bullish. CTS has successfully executed a structural transformation. The double-digit growth in targeted non-automotive sectors combined with 250 bps of gross margin expansion proves the diversification strategy is highly accretive. While defense ordering delays and macro inflation warrant monitoring, the overall financial health and raised guidance floor show strong underlying momentum.
Key Themes
Medical and Industrial Segments Accelerating
Diversified end markets were the absolute engine of growth this quarter. Medical sales jumped 28% YoY, bolstered by multiple ultrasound program wins including a large non-invasive aesthetics award. Industrial sales rose 14% YoY, driven by strong OEM and distribution momentum with specific wins in heat pumps, pool and spa systems, and commercial appliances. Both segments carry book-to-bill ratios well over 1.20, pointing to continued strength.
Favorable Mix Shift Drives Margin Expansion
Adjusted Gross Margin expanded by a massive 250 basis points to 39.5%. Management explicitly tied this to operational improvements and a favorable product mix. As the higher-margin Medical and Industrial products comprise a larger share of the total revenue pie (now 57%), CTS is experiencing structural, rather than cyclical, margin improvement.
Transportation Segment Reversing Declines
After declining 7% in FY25 and posting flat growth in late 25Q4, Transportation sales grew 3% in Q1. CTS won new business by expanding its sensing portfolio, notably adding an accelerometer application for a North American OEM. Total booked business remains a healthy $1.1 billion, offering long-term revenue visibility despite challenging end-market volumes.
Aerospace & Defense Order Timing Contradicts Growth Narrative
While overall bookings were strong, the Aerospace & Defense segment posted a surprisingly weak book-to-bill ratio of 0.75. Management anticipates an improvement in program funding throughout the rest of the year, but this specific data point highlights an ongoing vulnerability: the segment's heavy reliance on unpredictable government funding and procurement cycles.
Macro Headwinds: Tariffs and Commodity Inflation
Management highlighted ongoing vigilance regarding Section 232 tariffs on steel and aluminum, as well as inflation in precious metals and petroleum-based products. CTS is relying on operational agility and pricing actions to offset these costs, but a sudden spike in raw material prices could pressure the 39.5% gross margin going forward.
Light Vehicle Production Outlook
Despite securing new sensing wins, CTS faces a macro headwind in its legacy business: global light vehicle production in 2026 is expected to be slightly down year-over-year. The company must consistently win new content-per-vehicle simply to keep the Transportation segment flat.
Other KPIs
Stable. Up from $11.0M in 25Q1, representing a healthy 69% conversion of adjusted net earnings. Operating cash flow grew $1.8M to $17.3M, keeping the balance sheet highly liquid. CTS prioritized this cash for shareholder returns, distributing $10M through buybacks and dividends in Q1.
Stable. Down slightly from 18.3% in 25Q1, indicating efficient management of short-term capital needs despite robust double-digit sales growth. Net inventory increased moderately to $57.3M from $52.9M at the end of 2025, necessary to support the accelerating order book.
CTS maintains a strong net cash position. The balance sheet provides significant dry powder for potential strategic M&A, particularly as the company seeks to further bolster its Diversified End Markets portfolio.
Guidance
Decelerating. The company narrowed its guidance by raising the lower end (previously $550-$580M). At the midpoint ($570M), this implies ~5.3% YoY growth compared to FY25's $541.3M. While healthy, this represents a deceleration from the 11% growth achieved in 26Q1, indicating management expects the pace to normalize or is baking in conservatism regarding macro headwinds.
Decelerating. Raised the lower end from prior guidance ($2.30-$2.45). The midpoint of $2.40 implies ~7.6% growth over FY25's $2.23. This is a sharp deceleration from the 41% EPS growth logged in 26Q1, reflecting tougher YoY comps in the back half of the year and cautious assumptions around supply chain and tariff costs.
Key Questions
A&D Funding Visibility
Aerospace & Defense book-to-bill was notably soft at 0.75. What specific programs are experiencing funding delays, and what gives you confidence that these orders will materialize later in the year rather than being permanently cut?
Tariff Pass-Through Capabilities
You noted active management of Section 232 tariffs and raw material inflation. How much of these cost increases are contractually passed through to customers, versus requiring active renegotiation, particularly in the softer Transportation segment?
M&A Pipeline Actionability
With nearly $91 million in cash, manageable debt, and a soaring stock currency, you have significant dry powder. Are valuations in the Medical and Industrial target spaces becoming more reasonable, and should we expect a transaction to be announced this calendar year?